|Articles|April 28, 2016

eBook: Cardiac Safety Assessment Update

This special report offers an article regarding current FDA thinking and future direction with these assessments. ERT-a cloud platform solutions provider that captures quality efficacy and safety endpoints in centralized Cardiac Safety, Respiratory, Suicide Risk Assessment, and Clinical Outcome Assessments-offers expert view on this regulatory change.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Trending on Applied Clinical Trials Online

eBook: Cardiac Safety Assessment Update

Related Content

ACT Brief: Data Standardization Bottleneck in Real-Time Monitoring, US Biotech FIH Trial Regulatory Frustration, and FDA Approval of Zenbexus for Multiple Myeloma

Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV

Survey Finds US Biotechs Prefer Domestic First-in-Human Trials but FDA Hurdles Are Pushing Them Abroad

ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced

The CRA of the Future: From Monitoring Activity to Strategic Site Partnership

Trending on Applied Clinical Trials Online

ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced

Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program

ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps

Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV

Survey Finds US Biotechs Prefer Domestic First-in-Human Trials but FDA Hurdles Are Pushing Them Abroad